Synergistic anti-tumor effects of dabigatran etexilate and cyclophosphamide co-treatment are associated with decreased circulating tissue factor positive microparticles

被引:0
|
作者
Alexander, Eric T. [1 ]
Minton, Allyson R. [1 ]
Hayes, Candace S. [1 ]
Goss, Ashley [2 ]
Van Ryn, Joanne [3 ]
Gilmour, Susan K. [1 ]
机构
[1] Lankenau Inst Med Res, Wynnewood, PA USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ridgefield, CT USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
关键词
D O I
10.1158/1538-7445.AM2015-392
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
392
引用
收藏
页数:2
相关论文
共 2 条
  • [1] Synergistic anti-tumor effects with dabigatran etexilate and cisplatin in a murine ovarian cancer model
    Alexander, E.
    Hayes, C.
    Minton, A.
    Jain, K. B.
    Goss, A.
    Van Ryn, J.
    Gilmour, S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 232 - 232
  • [2] Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.
    Malorni, L.
    Hilsenbeck, S. G.
    Soliz, R. D.
    Ward, R. M.
    Ryan, A. J.
    Osborne, K. C.
    Schiff, R.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 808S - 808S